盐酸普拉克索联合美多巴治疗血管性帕金森病的疗效观察

目的评估盐酸普拉克索联合美多巴治疗血管性帕金森综合征的临床疗效。方法入选134例患者,随机分为吡贝地尔组48例、普拉克索组44例,对照组42例,各组患者诊断符合血管性帕金森综合征的诊断标准,年龄、性别、症状、体征及病程等具有可比性。对照组给予吡贝地尔片、美多巴片,疗程16周;治疗组给予盐酸普拉克索片、美多巴片,疗程16周。并于治疗4、6、16周后观察临床疗效。结果与对照组相比,各治疗组UPDRS评分均有显著性下降（P〈0．05）,临床疗效明显提高（P〈0．05）。与吡贝地尔组相比,普拉克索组显效率（P〈0．01）与总有效率均明显优于吡贝地尔组（P〈0．05）。结论盐酸普拉克索联合美多巴治疗血管性帕金森综合征效果满意,值得推广应用。     

分析研究左旋多巴联合普拉克索治疗帕金森病的有效性及安全性

目的：研究分析左旋多巴联合普拉克索治疗帕金森病的临床疗效,观察其有效性及安全性。方法选取在本院治疗的帕金森病88例患者,将患者随机分成实验组和对照组,每组44例,实验组采用左旋多巴联合普拉克索治疗,对照组采用左旋多巴治疗,观察两组患者治疗后的抑郁症专业量表（HAMD）评分。结果两组患者在治疗后, HAMD评分明显低于治疗前患者HAMD评分,但治疗12周后,实验组的患者HAMD评分明显优于对照组的患者,差异具有统计学意义（P〈0.05）。结论对于帕金森病的患者采用左旋多巴联合普拉克索治疗的临床效果较显著,且安全可靠,在临床上值得推广应用。     

普拉克索联合左旋多巴治疗帕金森病的疗效观察

目的分析普拉克索联合左旋多巴治疗帕金森病的临床疗效。方法 78例帕金森病患者随机分为治疗组和对照组各39例。对照组给予左旋多巴治疗,治疗组服用左旋多巴外,加用普拉克索。结果治疗组效果好于对照组,差异有统计学意义(P<0.05)。结论普拉克索联合左旋多巴治疗帕金森病疗效满意,不良反应少,能明显提高帕金森患者生活质量,值得临床推广。     

小剂量盐酸普拉克索治疗帕金森病患者吞咽功能障碍的临床研究

目的观察多巴胺受体激动剂盐酸普拉克索治疗帕金森病(PD)患者吞咽功能障碍的疗效和安全性。方法 32例PD伴吞咽功能障碍患者随机分成对照组和普拉克索组。对照组16例继续使用不同剂量的金刚烷胺、多巴丝肼(美多巴);普拉克索组16例在对照组的基础上加用小剂量盐酸普拉克索治疗。两组患者在用药前和用药后第8周均采用藤岛一郎吞咽评分和才藤吞咽障碍分级进行评价。结果普拉克索组PD吞咽功能障碍的藤岛一郎吞咽障碍评分和才藤吞咽障碍分级和对照组比较,差异均有统计学意义(P<0.01)。结论多巴胺受体激动剂盐酸普拉克索治疗帕金森病患者吞咽功能障碍是安全有效的。     

多巴丝肼联合盐酸普拉克索治疗帕金森病对运动功能的影响研究

目的探究帕金森病患者应用多巴丝肼联合盐酸普拉克索治疗对运动功能的影响。方法100例帕金森病患者,随机分为对照组与观察组,各50例。对照组患者给予多巴丝肼治疗,观察组患者给予多巴丝肼联合盐酸普拉克索治疗。比较两组患者的运动功能和不良反应发生情况。结果观察组患者左手运动、右手运动、起立、转弯、10 m折返运动时间分别为(94.06±5.23)、(98.64±8.03)、(3.03±0.25)、(4.44±0.84)、(13.48±0.72)min,均长于对照组的(86.13±4.02)、(88.65±5.46)、(2.23±0.12)、(2.98±0.48)、(13.94±0.62)min,差异有统计学意义(P<0.05)。治疗前及治疗4周,两组帕金森病综合评分量表(UPDRS)评分比较差异无统计学意义(P>0.05);观察组治疗8、12周UPDRS评分均低于对照组,差异有统计学意义(P<0.05)。两组不良反应发生率比较差异无统计学意义(χ2=3.053,P>0.05)。结论应用多巴丝肼联合盐酸普拉克索治疗帕金森病患者效果显著,可有效改善运动功能,临床价值高。     

左旋多巴/苄丝肼治疗帕金森病39例临床疗效观察

目的探讨左旋多巴/苄丝肼（美多巴）治疗帕金森病的临床疗效。方法选择我院73例帕金森病患者,随机分为2组,治疗组39和对照组34。对照组给予常规药物治疗。治疗组在对照组基础上给予美多巴和司来吉兰治疗。疗程均为3个月,对2组患者治疗前后进行帕金森病症状评分量表（UPDRS）评分,并且评定2组的治疗效果。结果治疗组治疗后UPDRS评分改善情况显著优于对照组,差异有统计学意义（P〈0.01）;治疗组总有效率为89.7%,高于对照组的70.5%,差异有统计学意义（P〈0.01）。结论在常规治疗基础上口服美多巴治疗帕金森病,临床治疗效果显著,值得临床借鉴。     

普拉克索联合多巴丝肼治疗帕金森综合征患者的疗效及对患者植物神经功能紊乱的影响

目的:观察普拉克索联合多巴丝肼治疗帕金森综合征患者的疗效及对患者植物神经功能紊乱的影响.方法:选取我院2010-03～2021-03治疗的帕金森综合征患者82例作为研究对象,随机数字表法分为对照组和观察组各41例,对照组给予口服多巴丝肼治疗,观察组在对照组基础上给予口服普拉克索治疗.比较两组患者的病情、植物神经功能(自主神经功能)、认知功能及精神状态的改善情况,评价临床治疗疗效.结果:观察组患者治疗后SCOPT-AUT评分、UPDRS评分较对照组低,MoCA评分、MMSE评分较对照组高(P＜0.05);观察组总有效率高于对照组(P＜0.05).结论:普拉克索联合多巴丝肼治疗帕金森综合征患者,可以改善患者的植物神经功能、认知功能及精神状态,控制患者的病情发展,提高临床疗效.     

分析探讨左旋多巴联合普拉克索治疗帕金森的有效性及安全性

目的：观察左旋多巴联合普拉克索治疗帕金森的有效性及安全性。方法选取2012年~2013年来本院进行治疗的帕金森患者60例,通过计算机随机分组的方式将其分为实验组和对照组,每组患者均为30例。实验组患者给予左旋多巴联合普拉克索,对照组患者给予左旋多巴,观察两组患者经过3个月的治疗后帕金森病评定量表评分,以及不良反应发生情况。结果实验组患者经过3个月的治疗后帕金森病评定量表评分显著小于对照组（P〈0.05）,且实验组的不良反应发生率也要显著小于对照组（P〈0.05）。结论左旋多巴联合普拉克索治疗帕金森病的疗效显著,安全性高。     

美多芭联合普拉克索治疗帕金森病的疗效和安全性探讨

目的 探讨多巴丝肼片(商品名:美多芭)联合普拉克索治疗帕金森病(PD)的疗效和安全性.方法 112例PD患者,随机分为对照组和观察组,各56例.对照组单用美多芭治疗,观察组使用美多芭联合普拉克索治疗.对比两组临床疗效、治疗前后帕金森氏病综合评分量表(UPDRS)评分及不良反应发生情况.结果 观察组治疗总有效率94.64...     

盐酸普拉克索治疗帕金森病伴发抑郁45例分析

目的分析盐酸普拉克索治疗帕金森病伴发抑郁后的临床疗效。方法选择我市四家三级甲等医院收治的帕金森病伴发抑郁患者共90例为观察对象,随机分为观察组和对照组各45例,两组均予以帕金森常规药物治疗,针对抑郁对照组给予安慰剂口服l片,3次/日,早、中、晚各l次,观察组患者给予盐酸普拉克索,药物剂量为0.25mg,每日2次,病情较重者可给予每日最大量剂量4.5mg,每次1.5mg,每日用药3次。观察记录两组患者12周后的治疗效果。结果观察组总有效率88.89%明显高于对照组总有效率62.22%,两组比较χ2=8.66差异有显著性意义(P<0.05)。结论盐酸普拉克索治疗帕金森病伴发抑郁患者效果满意,值得临床应用。     

普拉克索与多巴丝肼治疗帕金森病的成本效果分析

目的 比较单用多巴丝肼与合用普拉克索治疗帕金森病两种方法效果.方法 采用对照研究方法,比较多巴丝肼治疗组(A组)及合用普拉克索治疗组(B组)的治疗效果及治疗成本.结果 B组虽然在药物费用及治疗费用方面较A组明显增加(P＜0.01),但其帕金森病综合量表评分显著下降(P＜0.05),而且在帕金森病各期均可应用.结论 联合应用普拉克索虽会加重药物成本及治疗成本,但在改善帕金森病各期临床症状方面效果更好,且可应用于不同分期的帕金森病患者,应个体化推荐.     

普拉克索联合多巴丝肼片治疗帕金森病的效果及其对患者生活质量的影响

目的 探究在普拉克索与多巴丝肼片联合治疗帕金森病(PD)患者的临床效果及对患者生活质量的影响.方法 48例帕金森病患者,通过双盲法分为常规组与联合组,每组24例.常规组采用多巴丝肼片治疗,联合组在常规组基础上加入普拉克索治疗.比较两组患者治疗效果以及治疗前后生活质量.结果 联合组治疗总有效率91.67％高于常规组的54...     

Influences of levodopa on adipose tissue and skeletal muscle metabolism in patients with idiopathic Parkinson’s disease

OBJECTIVE: The substantial weight loss in Parkinson's patients may be related to direct influences of levodopa treatment on fat mobilization/oxidation. We assessed systemic and local metabolic responses to levodopa/benserazide in patients with idiopathic Parkinson's disease. METHODS: We studied 10 Parkinson's disease patients and examined adipose tissue and skeletal muscle metabolism directly with microdialysis. We monitored dialysate concentrations of ethanol, glucose, lactate, pyruvate, and glycerol to assess tissue blood flow and metabolism before and after levodopa/benserazide intake. We also conducted in vitro studies on adipocytes from healthy women. RESULTS: Levodopa/benserazide increased serum levodopa, 3,4-dihydroxyphenylacetic acid (DOPAC), and norepinephrine (P < 0.01). Serum adipose tissue and skeletal muscle glycerol did not change or decreased. Adipose tissue glycerol was inversely correlated with serum levodopa concentrations (P < 0.05). In isolated adipocytes, levodopa attenuated isoproterenol-induced glycerol release (P < 0.05). CONCLUSION: Levodopa/benserazide elicits pronounced metabolic changes in both adipose tissue and skeletal muscle with a switch from lipid to carbohydrate metabolism. In adipose tissue, levodopa/benserazide failed to activate lipolysis. Therefore, we suggest that levodopa/benserazide does not induce fat wasting through direct and acute influences on adipose tissue metabolism.     

Advances in the treatment of Parkinson's disease

Pharmacological treatment of Parkinson's disease has been advanced by a better understanding of how to use currently existing drugs as well as by the introduction of newer drugs. Three new dopaminergic agonists, ropinirole, pramipexole and cabergoline, have been introduced recently for the treatment of Parkinson's disease. A new class of drugs, COMT inhibitors, such as tolcapone, also have been introduced into clinical practice. These drugs extend the effect of levodopa therapy. The results of clinical trials such as the 5-year Sinemet study indicate that low-dose levo-dopa therapy can control motor symptoms up to 5 years with the minimal prevalence of adverse reactions. Pharmacology, efficacy and adverse reactions of these compounds will be discussed as well as their place in the treatment of Parkinson's disease.     

普拉克索片联合美多芭治疗帕金森病的疗效分析

目的探讨普拉克索片联合多巴丝肼片(商品名:美多芭)治疗帕金森病的疗效。方法88例帕金森病患者,随机分为研究组和对照组,每组44例。研究组患者给予普拉克索片联合美多芭治疗,对照组患者给予美多芭单药治疗。比较两组患者治疗前后统一帕金森病评定量表(UPDRS)评分、简易精神状态评价量表(MMSE)评分和临床疗效、不良反应发生情况。结果治疗后,研究组患者UPDRS评分(35.22±6.35)分明显低于对照组的(38.05±6.49)分,MMSE评分(26.38±4.69)分明显高于对照组的(23.29±3.19)分,差异具有统计学意义(P<0.05)。研究组患者总有效率为86.4%,明显高于对照组的68.2%,差异具有统计学意义(P<0.05)。两组患者不良反应发生率比较差异无统计学意义(P>0.05)。结论普拉克索片联合美多芭治疗帕金森病可明显改善患者的运动症状与认知功能。     

普拉克索治疗老年帕金森病伴发抑郁的疗效观察

目的探讨普拉克索对老年帕金森病(PD)伴发抑郁患者抑郁症状的临床疗效。方法将帕金森病合并抑郁的老年患者60例随机分为2组,即应用普拉克索和美多巴为治疗组,应用吡贝地尔缓释片和美多巴为对照组。收集两组病例治疗前后的Hamilton抑郁量表(HAMD)和统一帕金森病评分量表(UPDRS)评分。结果治疗组治疗后HAMD评分明显低于治疗前(P<0.05),对照组治疗后HAMD评分与治疗前比较,差异无统计学意义(P>0.05);两组治疗后UPDRS评分明显低于治疗前(P<0.05)。结论对于老年PD患者,普拉克索不仅可以改善运动状态,还可以明显改善抑郁症状。     

依达拉奉联合多巴丝肼片治疗血管性帕金森综合征疗效研究

目的 观察多巴丝肼片联合依达拉奉治疗血管性帕金森综合征的临床疗效,以期为血管性帕金森综合征的治疗提供借鉴。方法 以入榆林市星元医院就诊的血管性帕金森综合征患者为研究治疗对象,将患者随机分为观察组与对照组,对照组以多巴丝肼片治疗,观察组在对照组基础上予以依达拉奉治疗,治疗20 d,观察治疗前后临床症状与体征,采用帕金森病评定量表（UPDRS）评价临床疗效。结果 共搜集患者60例,每组各30例,各组在年龄、性别、分级、UPDRS评分、危险因素等方面具有可比性。观察组患者显效17例,有效11例,无效2例,总有效率为93.33%;对照组患者显效12例,有效10例,无效8例,总有效率为73.33%。有效率比较,差异有显著性意义（P<0.05）,说明观察组有效率明显高于对照组;两组患者治疗后的精神情绪行为、日常生活活动评分和运动功能评分较治疗前均有所降低（P<0.05）,治疗后患者日常生活、行为精神情绪、运动检查等UPDRS评分的比较,差异有显著性（P<0.05）,观察组UPDRS评分改善明显高于对照组。所有患者治疗前后一般体格检查及血、尿常规,肝肾功能,心电图均在正常范围内,未出现严重不良反应。结论 依达拉奉联合多巴丝肼片治疗血管性帕金森综合征的临床疗效要优于单独使用多巴丝肼片,且具有良好的安全性。     

Rotigotine transdermal patch: a review of its use in the management of Parkinson's disease

A transdermal patch formulation of the non-ergolinic dopamine agonist rotigotine (Neupro) is indicated for use as monotherapy in the treatment of early-stage Parkinson's disease or, in the EU, as an adjunct to levodopa across all disease stages. Transdermal rotigotine is an effective and generally well tolerated addition to the armamentarium for the control of Parkinson's disease, with the once-daily transdermal patch system offering several practical advantages and the possible benefits of avoiding pulsatile dopaminergic stimulation. Transdermal rotigotine was superior to placebo in patients with early-stage and advanced Parkinson's disease, although noninferiority to the oral dopamine agonists ropinirole or pramipexole was not consistently demonstrated. Additional active comparator trials would be of interest. In the meantime, transdermal rotigotine offers a convenient new treatment option for patients with Parkinson's disease.     

Rotigotine transdermal patch: a review of its use in the treatment of Parkinson's disease

A transdermal patch formulation of the non-ergolinic dopamine agonist rotigotine (Neupro?) is indicated as monotherapy for the treatment of early Parkinson's disease and as combination therapy with levodopa throughout the course of the disease. Daily application of the rotigotine transdermal patch (referred to here as rotigotine) provided predictable release and absorption of rotigotine, with steady-state rotigotine concentrations reached within 1-2 days. In six large, well designed clinical trials, rotigotine was an efficacious treatment for Parkinson's disease. In early Parkinson's disease, rotigotine initiated without levodopa produced significantly greater improvements than placebo in the Unified Parkinson's Disease Rating Scale (UPDRS) summed motor and activities of daily living (ADL) scores, as well as significantly higher response rates. In a comparison with oral ropinirole, rotigotine did not meet a prespecified response-rate noninferiority criterion, although this may reflect the dosages used, which may not have been directly comparable. In advanced Parkinson's disease, rotigotine in combination with levodopa reduced 'off' time and improved motor functioning and ADL significantly more than levodopa plus placebo. Rotigotine was noninferior to oral pramipexole in reducing 'off' time, although it did not meet a response-rate noninferiority criterion. A recent trial focused on both motor and non-motor endpoints in patients with inadequate early morning motor control despite antiparkinsonian treatment (most received levodopa). Rotigotine improved morning motor functioning and reduced sleep disturbances, night-time motor symptoms, depressive symptoms, pain and functioning, and quality of life to a significantly greater extent than placebo. Rotigotine was generally well tolerated across the trials and in longer-term extension studies, with the most common treatment-emergent adverse events being application-site reactions, gastrointestinal disturbances, somnolence and headache. Application-site reactions were generally mild to moderate in severity; where reported, up to 3% of patients had severe skin reactions. Thus, rotigotine offers a novel approach to the treatment of Parkinson's disease and, given its ease of administration, efficacy in reducing disabling motor and non-motor symptoms, and acceptable tolerability profile, it has the potential to be an attractive treatment option for this highly debilitating disease.